---
layout: default
title: Diazoxide
parent: 僅模型預測 (L5)
nav_order: 113
evidence_level: L5
indication_count: 10
---

# Diazoxide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Diazoxide: Insufficient Data for Repurposing Analysis

## One-Sentence Summary

Diazoxide (DB01119) is a drug with no current New Zealand market authorization.
The TxGNN pipeline did **not return any predicted new indications** for this candidate at this time,
and key data fields including original indication and mechanism of action remain unavailable.
**No evidence-based recommendation can be issued until data gaps are resolved.**

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current dataset |
| Predicted New Indication | None returned by TxGNN |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction stage not yet reached |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why Analysis Cannot Proceed

Two blocking data gaps prevent standard repurposing analysis:

**Mechanism of Action (MOA) is unavailable.** Without understanding how diazoxide exerts its pharmacological effect, it is not possible to assess whether a predicted new indication shares mechanistic overlap with known therapeutic applications. MOA data can be retrieved from the DrugBank API using identifier DB01119.

**Original indication data is absent.** The regulatory dataset returned zero New Zealand product licenses, and no approved indication text is available to establish a baseline therapeutic context. Without this anchor, the "from X to Y" repurposing narrative cannot be constructed, and cross-indication plausibility cannot be evaluated.

In addition, no TxGNN predicted indications were returned in this evidence pack. This may reflect a pipeline issue, a model confidence threshold not being met, or missing upstream graph embedding data. The root cause should be investigated before proceeding.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline returned no predicted indications for diazoxide, and both the original indication and mechanism of action data are missing. There is no analytical basis on which to build a repurposing case at this time.

**To proceed, the following is needed:**

- **Resolve DG002 (High):** Query the DrugBank API for DB01119 to retrieve mechanism of action, pharmacodynamics, and drug categories
- **Resolve DG001 (Blocking):** Download and parse the package insert PDF from the TFDA website to obtain approved indications, warnings, and contraindications
- **Investigate TxGNN output gap:** Confirm whether the empty `predicted_indications` array reflects a genuine model result (no confident predictions) or an upstream data pipeline failure
- **Supplement safety data:** Once the package insert is retrieved, populate key warnings, contraindications, and drug interaction data before safety screening can proceed
- **Re-run evidence pack generation** after all data gaps are resolved to enable a full L1–L5 evidence assessment
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

